Loading...

We've got a brand new version of Simply Wall St! Try it out

Pure Global Cannabis

TSXV:PURE
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PURE
TSXV
CA$14M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Pure Global Cannabis Inc. produces cannabis products for the medical and adult-use markets in Canada. The last earnings update was 82 days ago. More info.


Add to Portfolio Compare Print
  • Pure Global Cannabis has significant price volatility in the past 3 months.
PURE Share Price and Events
7 Day Returns
-5.3%
TSXV:PURE
-6.6%
CA Pharmaceuticals
-1.4%
CA Market
1 Year Returns
-67.9%
TSXV:PURE
-16.9%
CA Pharmaceuticals
-4.4%
CA Market
PURE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Pure Global Cannabis (PURE) -5.3% -14.3% -40% -67.9% - -
CA Pharmaceuticals -6.6% -10.4% -30.5% -16.9% 379.4% 363.4%
CA Market -1.4% -2.7% -3.1% -4.4% 3.4% -3.3%
1 Year Return vs Industry and Market
  • PURE underperformed the Pharmaceuticals industry which returned -16.9% over the past year.
  • PURE underperformed the Market in Canada which returned -4.4% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Pure Global Cannabis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Pure Global Cannabis. This is due to cash flow or dividend data being unavailable. The share price is CA$0.09.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Pure Global Cannabis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Pure Global Cannabis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSXV:PURE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in CAD CA$-0.20
TSXV:PURE Share Price ** TSXV (2019-08-16) in CAD CA$0.09
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 16.44x
Canada Market PE Ratio Median Figure of 532 Publicly-Listed Companies 13.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Pure Global Cannabis.

TSXV:PURE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:PURE Share Price ÷ EPS (both in CAD)

= 0.09 ÷ -0.20

-0.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pure Global Cannabis is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Pure Global Cannabis is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Pure Global Cannabis's expected growth come at a high price?
Raw Data
TSXV:PURE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 249 Publicly-Listed Companies 0.9x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Pure Global Cannabis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Pure Global Cannabis's assets?
Raw Data
TSXV:PURE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in CAD CA$0.05
TSXV:PURE Share Price * TSXV (2019-08-16) in CAD CA$0.09
Canada Pharmaceuticals Industry PB Ratio Median Figure of 146 Publicly-Listed Pharmaceuticals Companies 2.21x
Canada Market PB Ratio Median Figure of 2,453 Publicly-Listed Companies 1.42x
TSXV:PURE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:PURE Share Price ÷ Book Value per Share (both in CAD)

= 0.09 ÷ 0.05

1.67x

* Primary Listing of Pure Global Cannabis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pure Global Cannabis is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Pure Global Cannabis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Pure Global Cannabis has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Pure Global Cannabis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pure Global Cannabis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
100.4%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Pure Global Cannabis expected to grow at an attractive rate?
  • Unable to compare Pure Global Cannabis's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Pure Global Cannabis's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Pure Global Cannabis's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSXV:PURE Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 100.4%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.9%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.4%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSXV:PURE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSXV:PURE Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-03-31 0 -11 -25
2018-12-31 -9 -23
2018-09-30 -4 -21
2018-06-30 -3 -4
2018-03-31 -1 -2
2017-12-31 -1 -1
2016-12-31 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Pure Global Cannabis is high growth as no earnings estimate data is available.
  • Unable to determine if Pure Global Cannabis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSXV:PURE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Pure Global Cannabis Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:PURE Past Financials Data
Date (Data in CAD Millions) EPS *
2019-03-31 -0.20
2018-12-31 -0.23
2018-09-30 -0.26
2018-06-30 -0.06
2018-03-31 -0.03
2017-12-31 -0.02
2016-12-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Pure Global Cannabis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of PURE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Pure Global Cannabis's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Pure Global Cannabis's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Pure Global Cannabis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Pure Global Cannabis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Pure Global Cannabis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Pure Global Cannabis's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Pure Global Cannabis does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Pure Global Cannabis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Pure Global Cannabis's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Pure Global Cannabis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Pure Global Cannabis Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:PURE Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.02 -25.49 8.51
2018-12-31 -23.42 7.32
2018-09-30 -21.34 5.87 0.01
2018-06-30 -3.65 3.60 0.01
2018-03-31 -1.89 1.93 0.00
2017-12-31 -0.95 1.14
2016-12-31 -0.86 0.79 0.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Pure Global Cannabis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Pure Global Cannabis has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Pure Global Cannabis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Pure Global Cannabis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Pure Global Cannabis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Pure Global Cannabis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Pure Global Cannabis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Pure Global Cannabis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Pure Global Cannabis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Pure Global Cannabis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Pure Global Cannabis Company Filings, last reported 4 months ago.

TSXV:PURE Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 8.35 10.74 3.55
2018-12-31 9.15 12.23 7.74
2018-09-30 11.92 10.08 14.75
2018-06-30 0.65 1.80 0.43
2018-03-31 1.39 0.01 0.69
2017-12-31 0.33 0.45 0.24
2016-12-31 0.59 0.01 0.64
  • Pure Global Cannabis's level of debt (128.6%) compared to net worth is high (greater than 40%).
  • Unable to establish if Pure Global Cannabis's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Pure Global Cannabis has less than a year of cash runway based on current free cash flow.
  • Pure Global Cannabis has less than a year of cash runway if free cash flow continues to grow at historical rates of 119.4% each year.
X
Financial health checks
We assess Pure Global Cannabis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Pure Global Cannabis has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Pure Global Cannabis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Pure Global Cannabis dividends.
If you bought CA$2,000 of Pure Global Cannabis shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Pure Global Cannabis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Pure Global Cannabis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSXV:PURE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.9%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.7%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Pure Global Cannabis has not reported any payouts.
  • Unable to verify if Pure Global Cannabis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Pure Global Cannabis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Pure Global Cannabis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Pure Global Cannabis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Pure Global Cannabis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Pure Global Cannabis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Pure Global Cannabis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mel Panchal
COMPENSATION CA$2,127,510
CEO Bio

Mr. Malay Panchal, also known as Mel, RPh, Bsc., PHm, is the Founder of Pure Global Cannabis Inc. and serves as its President, Chief Executive Officer and Treasurer. He also serves as the Chairman of Pure Global Cannabis Inc. and has been its Director since July 2018. He is a cannabis industry entrepreneur and executive bringing over 20 years of pharmaceutical, marketing and operational experience. he has extensive knowledge in the health care, medical cannabis, natural medicine, eCommerce, and mail order pharmacy operational proficiencies on a global scale. Mr. Panchal has a Bachelor of Science, Pharmacy from the University of Toronto.

CEO Compensation
  • Insufficient data for Mel to compare compensation growth.
  • Mel's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Pure Global Cannabis management team in years:

0.8
Average Tenure
  • The average tenure for the Pure Global Cannabis management team is less than 2 years, this suggests a new team.
Management Team

Mel Panchal

TITLE
Founder
COMPENSATION
CA$2M

Bhupender Gosain

TITLE
Chief Financial Officer
COMPENSATION
CA$148K

Vik Chopra

TITLE
Vice President of IT & Business Operations

Trupti Smit

TITLE
Director of Corporate & Legal Affairs

Stephen Pynn

TITLE
Vice President of Corporate Development
TENURE
1.1 yrs

Ross Hendry

TITLE
Vice President of Sales and Marketing
TENURE
0.8 yrs

Michael Lavergne

TITLE
Head of Global Supply Chain Services
TENURE
1.1 yrs

Sanjeev Goel

TITLE
Chief Medical Officer
TENURE
0.8 yrs

Joseph Choi

TITLE
Controller
TENURE
0.8 yrs

Vishwas Sawant

TITLE
General Manager
Board of Directors Tenure

Average tenure and age of the Pure Global Cannabis board of directors in years:

1.1
Average Tenure
66
Average Age
  • The average tenure for the Pure Global Cannabis board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mel Panchal

TITLE
Founder
COMPENSATION
CA$2M

Brian O'Neill

TITLE
Director
COMPENSATION
CA$28K
TENURE
1.1 yrs

Jane Pagel

TITLE
Director
COMPENSATION
CA$26K
TENURE
1.1 yrs

Albert Beraldo

TITLE
Director
COMPENSATION
CA$28K
AGE
66
TENURE
1.1 yrs

Chandra Panchal

TITLE
Director
COMPENSATION
CA$83K
AGE
69
TENURE
1.1 yrs

Jeffrey Zicherman

TITLE
Member of Advisory Board

Aaron Salz

TITLE
Member of Advisory Board
AGE
28

Trina Fraser

TITLE
Member of Advisory Board

Paul Sparkes

TITLE
Member of Advisory Board

Jim Youmans

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Pure Global Cannabis individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
05. Jul 19 Buy Malay Panchal Individual 05. Jul 19 05. Jul 19 140,000 CA$0.10 CA$13,260
26. Nov 18 Buy Malay Panchal Individual 26. Nov 18 26. Nov 18 25,000 CA$0.20 CA$5,000
26. Nov 18 Buy Chandrakant Panchal Individual 26. Nov 18 26. Nov 18 2,000 CA$0.20 CA$400
31. Oct 18 Buy Malay Panchal Individual 30. Oct 18 30. Oct 18 13,000 CA$0.27 CA$3,480
24. Oct 18 Buy Malay Panchal Individual 24. Oct 18 24. Oct 18 100,000 CA$0.26 CA$25,818
17. Oct 18 Buy Chandrakant Panchal Individual 17. Oct 18 17. Oct 18 2,000 CA$0.29 CA$580
20. Aug 18 Buy Malay Panchal Individual 20. Aug 18 20. Aug 18 70,000 CA$0.30 CA$20,650
X
Management checks
We assess Pure Global Cannabis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Pure Global Cannabis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Much Are Pure Global Cannabis Inc. (CVE:PURE) Insiders Spending On Buying Shares?

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' Check out our latest analysis for Pure Global Cannabis Pure Global Cannabis Insider Transactions Over The Last Year There wasn't any very large single transaction over the last year, but we can still observe some trading. … While Pure Global Cannabis insiders bought shares last year, they didn't sell. … TSXV:PURE Recent Insider Trading, July 16th 2019 Pure Global Cannabis Insiders Bought Stock Recently Over the last three months, we've seen a bit of insider buying at Pure Global Cannabis.

Simply Wall St -

Do Insiders Own Lots Of Shares In Pure Global Cannabis Inc. (CVE:PURE)?

If you want to know who really controls Pure Global Cannabis Inc. … Pure Global Cannabis is a smaller company with a market capitalization of CA$35m, so it may still be flying under the radar of many institutional investors. … Check out our latest analysis for Pure Global Cannabis

Simply Wall St -

How Many Insiders Bought Pure Global Cannabis Inc. (CVE:PURE) Shares?

We often see insiders buying up shares in companies that perform well over the long term. … The Last 12 Months Of Insider Transactions At Pure Global Cannabis. … In the last twelve months there was more buying than selling by Pure Global Cannabis insiders

Simply Wall St -

Company Info

Description

Pure Global Cannabis Inc. produces cannabis products for the medical and adult-use markets in Canada. The company provides cannabis products, such as dried flower, cannabis oils, soft gels and capsules, seedlings and clones, vape pen cartridges, topicals, sublingual strip/spray, transdermal patch, and edibles and beverages, as well as wellness products. It offers its products under the PureSinse, SPARK Medical Cannabis clinics, and The Great Canadian Hemp Company brands. The company serves medical, pharmaceutical, wellness, health and beauty, natural health, food and beverage, and recreational legal markets. Pure Global Cannabis Inc. is headquartered in Toronto, Canada.

Details
Name: Pure Global Cannabis Inc.
PURE
Exchange: TSXV
Founded:
CA$14,274,946
158,610,513
Website: http://pureglobal.com
Address: Pure Global Cannabis Inc.
418-2095 Lake Shore Boulevard West,
Toronto,
Ontario, M8V 4G4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV PURE Common Shares TSX Venture Exchange CA CAD 11. Jul 2018
OTCPK PRCN.F Common Shares Pink Sheets LLC US USD 11. Jul 2018
BST 1QS Common Shares Boerse-Stuttgart DE EUR 11. Jul 2018
Number of employees
Current staff
Staff numbers
11
Pure Global Cannabis employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/18 01:14
End of day share price update: 2019/08/16 00:00
Last earnings filing: 2019/05/28
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.